電子型錄下載 品牌專區 行銷通路 商業合作 聯絡我們 網站導覽
English
中化產品網
個人清潔及美妝
聯夏食品
BOTANIST植物學家
BRISE人工智慧空氣清淨機
雪利
大王
欣樂樂愛思
綠芙特級
FINE
ONO
歐姆龍
台灣百靈佳殷格翰
EAPharma
統一
獅王
Garmin
樺達
依產品類別搜尋
搜尋
依公司名稱搜尋
搜尋
關鍵字搜尋 搜尋
ONO 首頁 > ONO
小野製藥
Ono Pharmaceutical Group
http://www.ono.co.jp

The Ono Pharmaceutical Group is "Dedicated to Man's Fight against Disease and Pain." Under this management philosophy, we are committed to fulfilling unmet medical needs. We aim to develop innovative new drugs that deliver true benefit to patients, and we strive to serve as an R&D-oriented, international pharmaceutical company specializing in defined areas.

We are highly aware of our responsibility as a pharmaceutical company dealing in medicinal drugs upon which human lives depend, and we are working to further strengthen our level of compliance to ensure that all our actions not only fully comply with all legal regulations but also are based on higher ethical standards.

In new drug research, our drug discovery activities focus on areas where we can fully benefit from the technologies and know-how we have accumulated and continue to exploit our strengths as well as on areas such as biotechnology based medicines where we can make effective use of genes we possess as our genetic assets. We are in active pursuit of the discovery and development of drugs that meet the unmet medical needs at the frontline of healthcare. The Global Discovery Research Alliance Headquarters established in our US base, Ono Pharma USA, Inc. (OPUS) in May 2008 is a powerful vehicle for promoting drug discovery alliances with bio-pharmaceutical companies in the US and Europe - plus research collaborations with universities and research institutions. Thus breakthrough drug discovery seeds and leading-edge technologies can be at our disposal to propel Ono's drug discovery research.

We are expanding our development pipeline by directing strong efforts into licensing activities including commercialization rights to new drug candidate compounds.

As for drug development, our first priority is in gaining licensing approval in Europe and the US to achieve new drug approval globally. Thus clinical development overseas is a key area of our endeavor.

For the purpose of further strengthening our global competitive position in new drug development, the Global Development Headquarters at OPUS was newly established in May 2008. Led by this US center, our international clinical development framework is ever strengthening.

Meanwhile, drug development in Japan focuses on obtaining early approval for compounds in late-stage development. We are also working on further speeding up the development speed of projects in their early development stage, filing by leveraging multinational clinical trials and global data for globally leading development programs.

The marketing division is actively working to enhance the reputation of Ono's innovative pharmaceuticals through presenting its scientific data mainly at workshops and lecture meetings and through the dissemination of high-quality information that is always backed by the latest medical knowledge, aimed at fulfilling the diversifying needs of healthcare professionals.

We envision that the NHI price revision and implementation of various healthcare cost containment policies may significantly and adversely affect our business. However, we will strive to attain stable growth by launching new products and by enhancing sales of existing products.

With top priority given to the pursuit of quality assurance of our products, the manufacturing division is placing stronger emphasis on improving both its hardware, and software and on establishing an efficient production management system.

Distribution of profits to all our shareholders is one of our key management policies, and we place great importance on the maintenance of stable dividends based on business performance. With respect to the three year period from Fiscal 2007 to Fiscal 2009, the company has set a total payout ratio of 100% as its target figure on a free cash flow basis, aggregating dividends and acquisition of its own shares. 

胰活愛